Semaglutide and GLP-1 Receptor Signaling

What is semaglutide's effect on GLP-1 receptor signaling?

Overview

Semaglutide acts as a full agonist at the GLP-1 receptor (GLP-1R), a class B1 G protein-coupled receptor. The signaling mechanism is more complex than initially thought.

The canonical pathway: Gs/cAMP

Semaglutide was engineered for maximal Gαs coupling, which activates adenylyl cyclase and increases intracellular cAMP. In pancreatic beta cells, the rise in cAMP drives PKA activation and promotes glucose-dependent insulin secretion. Notably, semaglutide generates a sustained cAMP response even after the peptide is washed out. This suggests that some internalized receptors continue signaling from endosomal compartments, which is a mechanistic reason why GLP-1R agonists are more effective than GIP agonists in maintaining insulin secretion in type 2 diabetes.

β-arrestin recruitment and receptor desensitization

Following Gs activation, the GLP-1R is phosphorylated at three serine doublets in its cytoplasmic tail (at positions 441/442, 444/445, and 451/452). This process recruits β-arrestins, which contribute to receptor desensitization and internalization. β-arrestin 2, abundantly expressed in beta cells, terminates acute Gs signaling but is also essential for sustained signaling. Mice lacking β-arrestin 2 show an impaired acute cAMP response to semaglutide but better sustained responses due to reduced desensitization. Thus, β-arrestin recruitment limits the peak response while influencing the duration of signaling.

Biased agonism: semaglutide as a "balanced" agonist

Semaglutide is regarded as a full, relatively balanced agonist, activating both Gs/cAMP and β-arrestin pathways in roughly equal measures. However, studies suggest that biased GLP-1R agonists with less β-arrestin recruitment relative to Gs activation lead to greater weight loss outcomes. The biased analogue NNC5840 showed superior results in maximal body weight reduction compared to semaglutide, although it had lower in vivo potency. This indicates that the β-arrestin signaling of semaglutide could be a limiting factor in its therapeutic potential.

Tissue-specific and non-canonical signaling

In the brain, particularly the area postrema where semaglutide acts, it engages both Gs and Gq pathways. Disruption of Gs or cAMP signaling in area postrema neurons negated semaglutide-induced weight loss. Inhibition of PDE4 enhances and prolongs cAMP responses in these neurons, suggesting potential targets for enhancing semaglutide's central nervous system effects. Recent studies have shown conformational changes in GLP-1R upon semaglutide binding that influence this signaling cascade.

Beyond Gs and β-arrestin

In the gut and enteric nervous system, semaglutide-triggered GLP-1R activation appears to engage PI3K/Akt signaling, producing downstream CREB-mediated BDNF transcription, along with modulation of TGF-β/Smad2/3 pathways that reduce inflammation. Cardiovascular effects involve additional pathways that inhibit downstream ERK1/2 and NF-κB.

Summary

Overall, semaglutide's pharmacology at GLP-1R is primarily driven by Gs/cAMP, which promotes insulin secretion and related metabolic effects. However, β-arrestin-mediated desensitization affects both the kinetics and maximal efficacy of semaglutide. Recent research highlights semaglutide as a useful reference point amid the evolving landscape of biased agonists.